Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT

Joanne Blair,1* Andrew McKay,2 Colin Ridyard,3 Keith Thornborough,4 Emma Bedson,2 Matthew Peak,5 Mohammed Didi,1 Francesca Annan,6 John W Gregory,7 Dyfrig Hughes3 and Carrol Gamble2

1Department of Endocrinology, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
2Clinical Trials Research Centre, University of Liverpool, Liverpool, UK
3Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK
4Department of Diabetes, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
5Department of Research, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
6Paediatric and Adolescent Division, University College Hospital, London, UK
7Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK

*Corresponding author jo.blair@alderhey.nhs.uk

Declared competing interests of authors: Joanne Blair undertakes paid advisory work for, and has received funding for research, to attend academic meetings and to support a nursing salary from, Novo Nordisk Ltd (Gatwick, UK), a pharmaceutical company that manufactures some of the insulins used in the SubCutaneous Insulin: Pumps or Injections? (SCIPI) study. The work undertaken by Joanne Blair for Novo Nordisk Ltd relates to growth hormone therapy and not diabetes. Mohammed Didi has received payment for advisory work and funding to attend academic meetings and to support a nursing salary from Novo Nordisk Ltd. The work undertaken by Mohammed Didi for Novo Nordisk Ltd relates to growth hormone therapy and not diabetes. Mohammed Didi has received expenses from Merck Serono Ltd (Feltham, UK) to attend educational meetings. Carrol Gamble is a member of the Efficacy and Mechanism Evaluation Programme Board of the National Institute for Health Research. Dyfrig Hughes is a member of the Health Technology Assessment (HTA) Clinical Trials Board (2010–16), the HTA Funding Teleconference (2015–16) and the Pharmaceuticals Panel (2008–12). John W Gregory reports grants from Cardiff University during the conduct of the study, and membership of the HTA Commissioning Board (2010–14). John W Gregory received speaker fees from Pfizer Inc. and Eli Lilly and Company (Basingstoke, UK), fees for attending an advisory board for Eli Lilly and Company and financial assistance to attend annual meetings of the European Society for Paediatric Endocrinology from Sanofi Genzyme (Guildford, UK), Merck Serono Ltd, Ipsen and Novo Nordisk Ltd.

Published August 2018
DOI: 10.3310/hta22420
Plain English summary

Continuous subcutaneous insulin infusion versus multiple daily injections
Health Technology Assessment 2018; Vol. 22: No. 42
DOI: 10.3310/hta22420

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

People with type 1 diabetes cannot make insulin, a hormone that controls blood sugar levels. This type of diabetes is treated with insulin. Insulin can be given by injections at mealtimes, with additional injections in the evening and/or morning. Alternatively, insulin may be given by pumps that give a small amount of insulin continuously by a fine plastic tube and needle that goes under the skin.

Pump treatment costs more than treatment with injections. If pumps treat this type of diabetes better during childhood, then patients may not need as much medical care as adults. If there is no difference between injections and pumps, money may be better spent in other diabetes services.

We compared these two methods of treatment in 293 newly diagnosed children aged 7 months to 15 years. Half of the patients were treated with insulin pumps and half with injections. The method of insulin delivery was decided randomly; neither the doctor nor patient could choose which they received.

We measured how good each method was at controlling blood sugar levels, growth and weight gain, doses of insulin needed, side effects and quality of life (QoL) reported by parents and children. After 1 year, we compared these measurements. On average, children treated with continuous subcutaneous insulin infusion (CSII) had poorer blood glucose control, used more insulin and had more adverse effects than children who had multiple daily injections, but these results were not statistically significant. However, parents of children on CSII reported a small, but statistically significant, increase in QoL, but this was not observed in the child-reported QoL. In this study, pump treatment cost £1863 per patient per year more than injections. The results of our study are not necessarily true for children after the first year of diabetes. Further research is needed in children who have had diabetes for longer.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 08/14/39. The contractual start date was in August 2010. The draft report began editorial review in May 2017 and was accepted for publication in September 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2018. This work was produced by Blair et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
**NIHR Journals Library Editor-in-Chief**

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Director of the NIHR Dissemination Centre, University of Southampton, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NIce), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snook**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** journals.library@nihr.ac.uk